Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes

In this paper, we present the development of a computer-based repurposing approach to identify FDA-approved drugs that are potentially able to interfere with irisin dimerization. It has been established that altered levels of irisin dimers are a pure hallmark of lipodystrophy (LD) syndromes. Accordi...

Descripción completa

Detalles Bibliográficos
Autores principales: Flori, Lorenzo, Brogi, Simone, Sirous, Hajar, Calderone, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145865/
https://www.ncbi.nlm.nih.gov/pubmed/37108741
http://dx.doi.org/10.3390/ijms24087578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145865/
https://www.ncbi.nlm.nih.gov/pubmed/37108741
http://dx.doi.org/10.3390/ijms24087578

Ejemplares similares